

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional/ Organizational or Other Financial Benefit	Expert Witness
Antoine Sakr	Loma Linda University Medical Center, Department of Cardiology—Co-Director, Advanced Heart Failure and Transplant; Assistant Professor of Medicine	None	None	None	None	None	None
Kelly H. Schlendorf	Vanderbilt Heart and Vascular Institute—Co-Director, Advanced HF/Transplant Training Program; Assistant Professor in Medicine	None	None	None	None	None	None
Esther E. Vorovich	Northwestern University Feinberg School of Medicine—Assistant Professor in Medicine – Cardiology	<ul style="list-style-type: none"> • Argon Medical • Plexus‡ 	None	None	None	<ul style="list-style-type: none"> • Allomap†§ • Rex Medical‡ 	None

This table represents all healthcare relationships of committee members with industry and other entities by authors, including those not deemed to be relevant, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq \$10,000$ of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACCF Disclosure Policy for Writing Committees.

* Dr. Jessup was employed by University of Pennsylvania School of Medicine as a Professor of Medicine during most of the writing effort.

† No financial benefit.

‡ Significant relationship.

§ This disclosure was entered under the Clinical Trial Enroller category in the ACC's disclosure system. To appear in this category, the author acknowledges that there is no *direct* or *institutional* relationship with the trial sponsor, as defined in the ACCF Disclosure Policy for Document Development.

|| Dr. Mather was employed by Jefferson Heart Institute as Director, Advanced Heart Failure and the Sidney Kimmel Medical College of Thomas Jefferson University as the Lubert Family Professor of Cardiology during most of the writing effort.

ABIM indicates American Board of Internal Medicine; ACC, American College of Cardiology; ACP, American College of Physicians; AHA, American Heart Association; APFED, American Partnership for Eosinophilic Disorders; CDC, Centers for Disease Control and Prevention; HFSA, Heart Failure Society of America; ISHLT, The International Society for Heart & Lung Transplantation; NHLBI, National Heart, Lung, and Blood Institute; and NIH, National Institutes of Health.